1. Topiramate-induced severe electrolyte abnormalities and hypernatremia leading to central pontine myelinolysis
- Author
-
Luba Muaddi, Barbara Clark, and Omar Osman
- Subjects
Topiramate ,Resuscitation ,Case Report ,Neuropathology ,Renal tubular acidosis ,Electrolytes ,medicine ,Humans ,renal system ,Hypernatremia ,neuroimaging ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Anesthesia ,Myelinolysis, Central Pontine ,psychiatry (drugs and medicines) ,Central pontine myelinolysis ,Female ,medicine.symptom ,business ,Hyponatremia ,Myoclonus ,fluid electrolyte and acid-base disturbances ,medicine.drug - Abstract
Central pontine myelinolysis (CPM) develops due to acute hypernatremia from a normal baseline serum sodium in the setting of electrolyte abnormalities induced by topiramate use. Topiramate is a commonly used medication with several indications including migraines, myoclonic jerks and seizures. It has been reported to cause renal tubular acidosis and severe electrolyte abnormalities, which in turn predispose patients to neuropathology via renal concentration defects and osmotic shifts. Our patient is a 55-year-old woman with a history of multiple sclerosis and myoclonus on topiramate for several years who presented with weakness and was found to be profoundly hypokalemic. She went on to develop changes in mental status, motor deficits and evidence of CPM on MRI during her hospitalisation. Surprisingly, the patient never had hyponatremia; however, she had an acute rise in serum sodium from a normal baseline after fluid resuscitation with normal saline for hypotension during her admission.
- Published
- 2021
- Full Text
- View/download PDF